Prevalence of potentially inappropriate use of antiviral therapy with simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalised patients: a retrospective study in Beijing, China
About half of the patients use simnotrelvir-ritonavir and nirmatrelvir-ritonavir that might potentially be inappropriate. More extensive research is required to supplement the empirical evidence supporting COVID-19 therapeutics. Additionally, appropriate therapy requires collaboration with pharmacists and education on the appropriate use of COVID-19 therapeutics among physicians and patients.
Authors
- Wanying Chen
- Yuezhen Zhu (ORCID: https://orcid.org/0000-0002-3730-402X)
- Zhuoling An (ORCID: https://orcid.org/0000-0002-7996-5002)
- Jia Li (ORCID: https://orcid.org/0000-0001-7132-2574)
- Hui Yang (ORCID: https://orcid.org/0000-0002-1797-2215)
- Hui Zhang (ORCID: https://orcid.org/0000-0002-4198-2042)
- Yi Zhang (ORCID: https://orcid.org/0000-0001-9861-4681)
- Han Wu (ORCID: https://orcid.org/0000-0002-0844-025X)
- Chunguo Jiang (ORCID: https://orcid.org/0000-0003-4577-7529)
- Xintong Zhang
Institutions
- Capital Medical University (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Beijing Obstetrics and Gynecology Hospital (CN)
Publication Details
- Journal
- BMJ Open Respiratory Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/bmjresp-2024-003043
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40